Interview Questions

Project Creator's Questions

Q1. Please tell us about your clinical practice, background in treating IPF and research in the space. How many patients do you treat, and what is the first line of choice?

Added By: slingshot_insights

Q2. Fibrogen is currently enrolling 565 patients in P3 Zephyrus trial, where the primary endpoint is change in forced vital capacity (FVC) from baseline. How relevant is this data point, and what drugs compete well in FVC change?

Added By: slingshot_insights

Q3. In Fibrogen's Phase 2 trial of 103 patients, quantitative lung fibrosis volume was 24.8 ml for pamrevlumab-treated patients versus 86.4 ml for the placebo group at week 24, and after 48 weeks, pamrevlumab-treated patients reached a volume of 75.4 ml, vs placebo-treated patients volume of 151.5 ml. How significant of a change is it, and how does it compare to what you're using?

Added By: slingshot_insights

Q4. Galapagos is enrolling 1500 patients in its Phase 3 trial, of which changes in disease progression, frequency of respiratory-related hospitalizations, quality of life, and mortality are the secondary endpoints. Which of those would you be most interested in seeing data points and why?

Added By: slingshot_insights

Q5. In Galapagos' Phase 2 Flora trial, patients taking GLPG1690 had an increase of 8 mL in FVC), while those on placebo showed a reduction of 87 mL, after 12 weeks. How does it compare to Pamrevlumab's P2 data?

Added By: slingshot_insights

Q6. Which of the 3 upcoming therapies are you most excited about and why? How much of a need is there for them?

Added By: slingshot_insights

Join Project To Add Your Questions and Vote on Order

Project Participants' Questions

Q7. How much read-thru do the BMS-986020 results offer to GLPG-1690? Mechanistically how different are the two?
https://www.ncbi.nlm.nih.gov/pubmed/30201408

Added By: maurice

Q8. Does the trial design of GLPG1690/Biogen (with/without background therapy) vs. Fibrogen's monotherapy impact how you would use those therapies in practice (if all are approved)?

Added By: maurice

Q9. How eager are patients to enroll in the three programs? Is one more likely to enroll more rapidly than the others? Why?

Added By: maurice

Q10. Galapagos reported data using FRI by Fluida
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0918-5
which they claim shows disease progression earlier than FVC because effec ts in lower lobes can be detected before impact is made on FVC. The paper above actually is with Fibrogen data. If you are familiar, what are you thoughts on the technology particularly how it may pertain to ability to predict clinical success based on what Galapagos has seen with their 12 week study?

Added By: maurice